High-purity therapeutic RNA/DNA building blocks manufactured under rigorous ISO & cGMP guidelines, optimized for immediate dispatch to Czech biotechnology clusters and research institutes.
The global pharmaceutical landscape is witnessing a monumental transition toward nucleic acid therapeutics, specifically Small Interfering RNA (siRNA), Antisense Oligonucleotides (ASOs), MicroRNA (miRNA) mimics, and Aptamers. Driven by breakthroughs in target-specific gene silencing and liver/extra-hepatic delivery systems, Oligonucleotide Active Pharmaceutical Ingredients (APIs) have emerged as the foundational pillar for next-generation drug development.
Within Central and Eastern Europe (CEE), the Czech Republic has solidified its strategic position as a high-growth hub for biopharmaceutical innovation. Supported by prestigious academic centers such as the Institute of Organic Chemistry and Biochemistry (IOCB Prague), Charles University, and Masaryk University in Brno, the Czech market demands reliable, scalable, and ultra-high-purity oligonucleotide API manufacturing partners. As traditional small-molecule synthesis facilities pivot toward modern biologics, bridging high-capacity Asian chemical synthesis with European regulatory rigors (SUKL & EMA compliance) becomes imperative.
This comprehensive industry whitepaper delineates the technical, economic, and operational dynamics of sourcing Oligonucleotide APIs from top-tier Chinese manufacturing infrastructure to serve the rapidly expanding pharmaceutical industry in the Czech Republic and greater Europe.
The Czech Republic boasts one of Central Europe's most sophisticated clinical trial networks and life science infrastructures. With major biotech parks concentrated around Prague, Brno (South Moravian Innovation Centre - JIC), and Olomouc, local enterprises require specialized suppliers who understand both early-stage screening and commercial-scale batch validation.
Navigating the State Institute for Drug Control (SÚKL) standards requires complete CTD Section 3.2.S documentation, DMF filings, and rigorous viral safety and impurity profiling for all imported APIs.
Czech research centers lead innovation in targeted oncology, rare metabolic diseases, and novel drug delivery. Accessing scalable phosphoramidites and modified sequence oligonucleotides speeds up target discovery.
Oligonucleotide integrity relies on uninterrupted -20°C to -80°C logistics. Strategic shipping routes connecting East Asian production facilities directly to Vaclav Havel Airport Prague guarantee compound stability.
While European biopharma excels in therapeutic innovation, local manufacturing of commercial-grade oligonucleotide APIs often encounters high capital expenditures and capacity constraints. Chinese manufacturing ecosystems solve these bottlenecks through vertical integration, state-of-the-art automated synthesizer arrays, and comprehensive chemical precursor supply chains.
From nucleoside starting materials to specialized phosphoramidites (2'-OMe, 2'-F, GalNAc, LNA) and solid support resins (CPG and polystyrene), domestic backward integration guarantees supply chain security even during global disruptions.
Deploying advanced multi-column and continuous-flow liquid phase (LPOS) chemistry enables transition from gram-scale research quantities to multi-kilogram commercial batches with minimal batch-to-batch variation.
Specialized capabilities in terminal phosphorylation, phosphorothioate (PS) backbone stereocontrolled linkage, GalNAc cluster conjugation, cholesterol tags, and fluorophore labellings for enhanced metabolic stability.
Unmatched cost structures allow Czech pharmaceutical firms and CROs to optimize clinical budgets without compromising on stringent US FDA, EMA, or NMPA cGMP regulatory standards.
Comprehensive technical parameters supporting preclinical research through commercial API release for Czech and Central European partners.
| Parameter / Capability | Preclinical / Research Grade | Clinical Trial Grade (Phase I-III) | Commercial cGMP Grade |
|---|---|---|---|
| Synthesis Scale | 1 mmol - 50 mmol | 50 mmol - 500 mmol | 1 mol - Multi-Kilogram |
| Purity (IP-RP-HPLC) | ≥ 85% - 90% | ≥ 95.0% | ≥ 98.0% - 99.0% |
| Backbone Modifications | PO, PS (Phosphorothioate) | Stereopure PS, MP, PNA | Custom Backbone Engineering |
| Sugar Modifications | 2'-OMe, 2'-MOE, 2'-F | LNA, ENA, 2'-O-Propargyl | Proprietary Conjugated Sugar Units |
| Targeting Conjugates | Cholesterol, Biotin, FITC | GalNAc1, GalNAc3 Clusters | Custom Peptide/Antibody Conjugates |
| Analytical Verification | LC-MS, ESI-MS | HRMS, 1D/2D NMR, Bioburden | Full CTD Module 3 Validation, LC-MS/MS |
Gentolex’s overarching goal is to create seamless opportunities connecting global biopharmaceutical institutions with high-standard chemical synthesis services and verified APIs. Up to date, Gentolex Group has served clients across more than 10 countries, establishing direct representative channels to facilitate efficient regional communication.
Our core manufacturing site features an expansive construction area of 250,000 square meters operating under strict international cGMP standards. We offer flexible, scalable, and highly cost-effective solutions spanning Peptide APIs, Custom Peptides, Oligonucleotide APIs, FDF (Finished Dosage Form) licensing out, lab setup consulting, and end-to-end supply chain integration.
Comprehensive production capacities designed under global safety and quality norms, supporting intermediate custom synthesis from milligram to metric ton levels.
Extensive catalog of peptide and oligonucleotide APIs for analytical development, preclinical research, and commercial release. Full DMF, CEP, and EDMF regulatory package assistance provided.
Dedicated R&D teams skilled in route scouting, process optimization, impurity isolation, and validation for novel oligonucleotide candidates.
For European clients seeking to streamline vendor management, we offer tailor-made procurement solutions across our integrated, high-audit chemical supply chain.
Stay informed on recent developments in synthetic peptide APIs, neuroactive compounds, and oligonucleotide delivery systems serving global academic and industrial partners.
Selank Acetate is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from human tuftsin, researched for neuropharmacological applications and metabolic stability in Central European clinical trials.
Providing robust Tβ4 peptide active ingredients for biotechnology organizations involved in tissue repair, cell migration, and wound healing studies.
A synthetic pentadecapeptide investigated for its bio-protective properties. Available in multi-gram and batch quantities for European distribution.
Neuropeptide derived from ACTH fragment (4-10), synthesized with high enantiomeric purity for neuroprotective research applications.
Mitochondria-targeting tetrapeptide designed to selectively bind cardiolipin, supporting bioenergetics research across EU biotechnology laboratories.
Need modified sequences, specific isotope labels, or unique GalNAc configurations for your Czech lab?
Request Technical QuoteBrowse our extensive inventory of high-grade active ingredients, research peptides, and specialized amino acid intermediates available for worldwide shipment.
Technical details regarding analytical release, customs import regulations, cold-chain integrity, and batch scaling for European bio-pharmaceutical organizations.
Our manufacturing facilities operate in strict adherence to ICH Q7 GMP guidelines for Active Pharmaceutical Ingredients. For all exports serving the Czech Republic, we provide a complete Common Technical Document (CTD) Module 3 dossier package, certificates of analysis (CoA), BSE/TSE risk assessments, residual solvent analysis (ICH Q3C), elemental impurity profiles (ICH Q3D), and bioburden/endotoxin testing verification. This documentation enables seamless submission to SÚKL for clinical trial applications (CTA) and marketing authorization applications (MAA).
We specialize in a broad spectrum of chemical modifications designed to extend RNA serum half-life and enhance target cell uptake. Capabilities include 2'-O-Methyl (2'-OMe), 2'-Fluoro (2'-F), Locked Nucleic Acids (LNA), Phosphorothioate (PS) backbone linkages, terminal 5'-phosphate modifications, and trivalent N-acetylgalactosamine (GalNAc3) cluster conjugation tailored for hepatocyte targeting in siRNA therapeutics like Inclisiran and Givosiran analogs.
Oligonucleotides are lyophilized into stable sodium salts or purified free bases and sealed in nitrogen-purified container closure systems. Shipments to Czech biological institutes and pharma companies use temperature-monitored dry ice (-78.5°C) or validated sub-zero shipping containers equipped with real-time GPS and temperature dataloggers, guaranteeing zero degradation upon delivery.
Standard research-grade custom oligonucleotide sequences (1 to 50 mmol) are typically synthesized, purified by IP-RP-HPLC, and dispatched within 3 to 5 weeks. Clinical-grade cGMP batches requiring full validation, stability testing, and DMF compilation usually range between 10 to 16 weeks depending on sequence complexity and raw material availability.
Yes. Leveraging our dual expertise in custom peptide synthesis (e.g., cell-penetrating peptides) and solid-phase oligonucleotide assembly, we offer streamlined conjugation chemistries (maleimide-thiol, click chemistry, amide coupling) to create targeted POCs for cell-specific drug delivery research.
Whether you require gram-scale research custom synthesis or full commercial cGMP manufacturing for the Czech Republic and wider European markets, our dedicated scientific team is ready to assist.
Send Inquiry Now
